Benzilates
"Benzilates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D001561
|
MeSH Number(s) |
D02.241.223.601.238.306 D02.241.511.085
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzilates".
Below are MeSH descriptors whose meaning is more specific than "Benzilates".
This graph shows the total number of publications written about "Benzilates" by people in this website by year, and whether "Benzilates" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 | 2007 | 0 | 1 | 1 | 2008 | 0 | 1 | 1 | 2009 | 0 | 3 | 3 | 2010 | 0 | 1 | 1 | 2011 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzilates" by people in Profiles.
-
Zinner NR, Dmochowski RR, Staskin DR, Siami PF, Sand PK, Oefelein MG. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
-
Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
-
Sand PK, Johnson Ii TM, Rovner ES, Ellsworth PI, Oefelein MG, Staskin DR. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
-
Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009 Dec; 63(12):1715-23.
-
Dmochowski RR, Rosenberg MT, Zinner NR, Staskin DR, Sand PK. Extended-release trospium chloride improves quality of life in overactive bladder. Value Health. 2010 Mar-Apr; 13(2):251-7.
-
Sand PK, Dmochowski RR, Zinner NR, Staskin DR, Appell RA. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec; 20(12):1431-8.
-
Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar; 71(3):449-54.
-
Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4.
-
Sand PK. Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract. 2004 Oct; 16(10 Suppl):8-11.
-
Baron B, Kloog Y. Fatty acid incorporation increases the affinity of muscarinic cholinergic receptors for agonists. Biochim Biophys Acta. 1984 Oct 16; 801(3):342-50.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|